BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32951452)

  • 21. Patterns of brain metastasis immediately before prophylactic cranial irradiation (PCI): implications for PCI optimization in limited-stage small cell lung cancer.
    Chu X; Li S; Xia B; Chu L; Yang X; Ni J; Zou L; Li Y; Xie C; Lin J; Zhu Z
    Radiat Oncol; 2019 Sep; 14(1):171. PubMed ID: 31533763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Moderately Hypofractionated Once-Daily Compared With Twice-Daily Thoracic Radiation Therapy Concurrently With Etoposide and Cisplatin in Limited-Stage Small Cell Lung Cancer: A Multicenter, Phase II, Randomized Trial.
    Qiu B; Li Q; Liu J; Huang Y; Pang Q; Zhu Z; Yang X; Wang B; Chen L; Fang J; Lin M; Jiang X; Guo S; Guo J; Wang D; Liu F; Chu C; Huang X; Xie C; Liu H
    Int J Radiat Oncol Biol Phys; 2021 Oct; 111(2):424-435. PubMed ID: 33992717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.
    Le QT; Moon J; Redman M; Williamson SK; Lara PN; Goldberg Z; Gaspar LE; Crowley JJ; Moore DF; Gandara DR
    J Clin Oncol; 2009 Jun; 27(18):3014-9. PubMed ID: 19364954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients.
    Stinchcombe TE; Fan W; Schild SE; Vokes EE; Bogart J; Le QT; Thomas CR; Edelman MJ; Horn L; Komaki R; Cohen HJ; Kishor Ganti A; Pang H; Wang X
    Cancer; 2019 Feb; 125(3):382-390. PubMed ID: 30343497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation 
with Concurrent Twice-daily Radiotherapy for Patients 
with Limited-stage Small Cell Lung Cancer].
    You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):55-60. PubMed ID: 28103974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of risk factors for pulmonary complications in patients with limited-stage small cell lung cancer : A single-centre retrospective study.
    Sas-Korczyńska B; Łuczyńska E; Kamzol W; Sokołowski A
    Strahlenther Onkol; 2017 Feb; 193(2):141-149. PubMed ID: 27785518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemoradiotherapy duration correlates with overall survival in limited disease SCLC patients with poor initial performance status who successfully completed multimodality treatment.
    Manapov F; Klöcking S; Niyazi M; Belka C; Hildebrandt G; Fietkau R; Klautke G
    Strahlenther Onkol; 2012 Jan; 188(1):29-34. PubMed ID: 22189436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer.
    Flentje M; Huber RM; Engel-Riedel W; Andreas S; Kollmeier J; Staar S; Dickgreber N; Vaissiere N; De Almeida C; Edlich B; Fietkau R
    Strahlenther Onkol; 2016 Apr; 192(4):216-22. PubMed ID: 26809652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
    Senan S; Okamoto I; Lee GW; Chen Y; Niho S; Mak G; Yao W; Shire N; Jiang H; Cho BC
    Clin Lung Cancer; 2020 Mar; 21(2):e84-e88. PubMed ID: 31948903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concurrent or Sequential Chemoradiotherapy after 3-4 Cycles Induction Chemotherapy for LS-SCLC with Bulky Tumor.
    Zhao J; Zhang W; Er P; Chen X; Guan Y; Qian D; Wang J; Yuan Z; Zhao L; Wang P; Pang Q
    J Cancer; 2020; 11(17):4957-4964. PubMed ID: 32742443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study.
    Li C; Xiong Y; Zhou Z; Peng Y; Huang H; Xu M; Kang H; Peng B; Wang D; Yang X
    Med Oncol; 2014 Dec; 31(12):369. PubMed ID: 25416052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation.
    Videtic GM; Truong PT; Dar AR; Yu EW; Stitt LW
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):709-16. PubMed ID: 14529775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuron-specific enolase and response to initial therapy are important prognostic factors in patients with small cell lung cancer.
    Zhou M; Wang Z; Yao Y; Zhou H; Liu M; Sun J
    Clin Transl Oncol; 2017 Jul; 19(7):865-873. PubMed ID: 28127669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Irinotecan plus cisplatin chemotherapy followed by concurrent thoracic irradiation with low-dose weekly cisplatin for limited-disease small-cell lung cancer.
    Wahba HA; Halim AA; El-Hadaad HA
    Med Oncol; 2012 Mar; 29(1):199-204. PubMed ID: 21140241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.
    Rwigema JM; Verma V; Lin L; Berman AT; Levin WP; Evans TL; Aggarwal C; Rengan R; Langer C; Cohen RB; Simone CB
    Cancer; 2017 Nov; 123(21):4244-4251. PubMed ID: 28678434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
    Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N
    Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cisplatin and etoposide chemotherapy combined with early concurrent twice-daily thoracic radiotherapy for limited-disease small cell lung cancer in elderly patients.
    Okamoto K; Okamoto I; Takezawa K; Tachibana I; Fukuoka M; Nishimura Y; Nakagawa K
    Jpn J Clin Oncol; 2010 Jan; 40(1):54-9. PubMed ID: 19837690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
    Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M;
    J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy with concurrent brain and thoracic radiotherapy in brain-only metastases of treatment naive small-cell lung cancer: a phase II study.
    Chen LK; Huang H; Liao H; Liu GZ; Zeng YD; Dinglin XX; Xu GC; Wei WD
    Med Oncol; 2012 Sep; 29(3):1687-92. PubMed ID: 21853344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study.
    Niho S; Yoshida T; Akimoto T; Sakamaki K; Ono A; Seto T; Nishio M; Yamamoto N; Hida T; Okamoto H; Kurata T; Satouchi M; Goto K; Yamanaka T; Ohe Y
    Lung Cancer; 2020 Mar; 141():64-71. PubMed ID: 31955002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.